Novel link between prostaglandin E2 (PGE2) and cholinergic signaling in lung cancer: The role of c-Jun in PGE2-induced α7 nicotinic acetylcholine receptor expression and tumor cell proliferation
Corresponding Author
XiaoRong Zhong
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Laboratory of Molecular Diagnosis of Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Correspondence
Xiaorong Zhong, Laboratory of Molecular Diagnosis of Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China.
Tel: +86 2885422685
Fax: +86 2885422685
Email: [email protected]
Search for more papers by this authorYu Fan
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Search for more papers by this authorJeffrey D. Ritzenthaler
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Search for more papers by this authorWenJing Zhang
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Search for more papers by this authorKe Wang
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Search for more papers by this authorQingHua Zhou
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Search for more papers by this authorJesse Roman
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Louisville Veterans Affairs Medical Center, Louisville, Kentucky, USA
Search for more papers by this authorCorresponding Author
XiaoRong Zhong
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Laboratory of Molecular Diagnosis of Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Correspondence
Xiaorong Zhong, Laboratory of Molecular Diagnosis of Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China.
Tel: +86 2885422685
Fax: +86 2885422685
Email: [email protected]
Search for more papers by this authorYu Fan
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Search for more papers by this authorJeffrey D. Ritzenthaler
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Search for more papers by this authorWenJing Zhang
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Search for more papers by this authorKe Wang
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Search for more papers by this authorQingHua Zhou
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Search for more papers by this authorJesse Roman
Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
Louisville Veterans Affairs Medical Center, Louisville, Kentucky, USA
Search for more papers by this authorAbstract
Background
Cyclooxygenase-2-derived prostaglandin E2 (PGE2) stimulates tumor cell growth and progression. α7 nicotinic acetylcholine receptor (nAChR) is a major mediator of cholinergic signaling in tumor cells. In the present study, we investigated the mechanisms by which PGE2 increases non-small cell lung cancer (NSCLC) proliferation via α7 nAChR induction.
Methods
The effects of PGE2 on α7 nAChR expression, promoter activity, and cell signaling pathways were detected by Western blot analysis, real time reverse transcriptase polymerase chain reaction, and transient transfection assay. The effect of PGE2 on cell growth was determined by cell viability assay.
Results
We found that PGE2 induced α7 nAChR expression and its promoter activity in NSCLC cells. The stimulatory role of PGE2 on cell proliferation was attenuated by α7 nAChR small interfering ribonucleic acids (siRNA) or acetylcholinesterase. PGE2-induced α7 nAChR expression was blocked by an antagonist of the PGE2 receptor subtype EP4 and by EP4 siRNA. Furthermore, PGE2 enhanced α7 nAChR expression via activation of c-Jun N-terminal kinase (JNK), phosphatidylinositol 3-kinase (PI3-K), and protein kinase A (PKA) pathways followed by increased c-Jun expression, a critical transcription factor. Blockade of c-Jun diminished the effects of PGE2 on α7 nAChR promoter activity and protein expression, and cell growth.
Conclusion
Our results demonstrate that PGE2 promotes NSCLC cell growth through increased α7 nAChR expression. This effect is dependent on EP4-mediated activation of JNK, PI3K, and PKA signals that induce c-Jun protein expression and α7 nAChR gene promoter activity. Our findings unveil a novel link between prostanoids and cholinergic signaling.
References
- 1Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584–594.
- 2Paleari L, Cesario A, Fini M, Russo P. alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? Drug Discov Today 2009; 14: 822–836.
- 3Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7: 861–867.
- 4Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 2010; 13: 2–15.
- 5Park W, Oh YT, Han JH, Pyo H. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2. J Exp Clin Cancer Res 2008; 27: 66.
- 6Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–959.
- 7Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–1080.
- 8Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55: 115–122.
- 9Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 promotes lung cancer cell migration via EP4- betaArrestin1-c-Src signalsome. Mol Cancer Res 2010; 8: 569–577.
- 10Mao JT, Cui X, Reckamp K et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005; 7: 30–39.
- 11Krysan K, Kusko R, Grogan T et al. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res 2014; 12: 765–774.
- 12Song P, Sekhon HS, Fu XW et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 2008; 68: 4693–4700.
- 13Song P, Sekhon HS, Jia Y et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003; 63: 214–221.
- 14Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007; 37: 681–690.
- 15Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: Multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008; 29: 151–158.
- 16Han S, Ritzenthaler JD, Wingerd B, Roman J. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J Biol Chem 2005; 280: 33240–33249.
- 17Zhong XR, Li L, Wang M et al. A proteomic approach to elucidate the multiple targets of selenium-induced cell-growth inhibition in human lung cancer. Thorac Cancer 2011; 2: 164–178.
- 18Mexal S, Jenkins PM, Lautner MA, Iacob E, Crouch EL, Stitzel JA. alpha7 nicotinic receptor gene promoter polymorphisms in inbred mice affect expression in a cell type-specific fashion. J Biol Chem 2007; 282: 13220–13227.
- 19Han S, Sidell N, Roser-Page S, Roman J. Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression. Int J Cancer 2004; 111: 322–331.
- 20Körner A, Mudduluru G, Manegold C, Allgayer H. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer 2010; 103: 802–811.
- 21Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 2013; 65: 1010–1052.
- 22Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66: 9794–9797.
- 23Carrasco-Serrano C, Campos-Caro A, Viniegra S, Ballesta JJ, Criado M. GC- and E-box motifs as regulatory elements in the proximal promoter region of the neuronal nicotinic receptor alpha7 subunit gene. J Biol Chem 1998; 273: 20021–20028.
- 24Paleari L, Catassi A, Ciarlo M et al. Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 2008; 41: 936–959.
- 25Schaal C, Chellappan SP. Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res 2014; 12: 14–23.
- 26Sharma SD, Meeran SM, Katiyar SK. Proanthocyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E(2) and prostaglandin E(2) receptors. (Published erratum appears in Mol Cancer Ther 2012; 11: 2072–3) Mol Cancer Ther 2010; 9: 569–580.
- 27Brown KC, Lau JK, Dom AM et al. MG624, an alpha7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis 2012; 15: 99–114.
- 28Shin VY, Jin HC, Ng EK et al. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 2008; 233: 254–261.
- 29Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 2007; 97: 279–287.
- 30Shin VY, Wu WK, Ye YN et al. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis 2004; 25: 2487–2495.
- 31Löffler I, Grün M, Böhmer FD, Rubio I. Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2. BMC Cancer 2008; 8: 380.
- 32Nitta RT, Badal SS, Wong AJ. Measuring the constitutive activation of c-Jun N-terminal kinase isoforms. Methods Enzymol 2010; 484: 531–548.
- 33Bouskine A, Nebout M, Mograbi B, Brücker-Davis F, Roger C, Fenichel P. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology 2008; 149: 565–573.
- 34Battersby S, Sales KJ, Williams AR, Anderson RA, Gardner S, Jabbour HN. Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Human Reprod 2007; 22: 36–44.
- 35George RJ, Sturmoski MA, Anant S, Houchen CW. EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 2007; 83: 112–120.
- 36Chen D, Reierstad S, Lin Z et al. Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts. Cancer Res 2007; 67: 8914–8922.
- 37Matthews CP, Colburn NH, Young MR. AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007; 7: 317–324.
- 38Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008; 68: 7750–7759.
- 39Kikuchi J, Kinoshita I, Shimizu Y et al. Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells. Br J Cancer 2008; 99: 2013–2019.
- 40Zhang Y, Pu X, Shi M et al. Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 2007; 7: 145.
- 41Mauritz I, Westermayer S, Marian B, Erlach N, Grusch M, Holzmann K. Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells. Br J Cancer 2006; 94: 1718–1725.
Citing Literature
